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69 Rapid induction of high level azithromycin resistance in clinical
CF isolates
C. McGettigan1, C. Kenny1,2, L. Sherrard1, G. McCaughey1, S.J. McGrath1,
L. McIlreavey1, J.S. Elborn1, M. Tunney1. 1Queen’s University Belfast, CF &
Airways Microbiology Research Group, Belfast, United Kingdom; 2University
College Dublin, Dublin, Ireland
Objectives: The use of chronic azithromycin treatment has been linked with
increased macrolide resistance amongst respiratory pathogens. The aim of this
study was to determine if in vitro exposure to azithromycin induces resistance
among Streptococcus and Rothia isolates from CF sputum. We also determined the
stability of any resistance induced.
Methods: Development of resistance after serial exposure was investigated by pas-
saging Streptococcus (n = 6) and Rothia (n = 6) isolates in sub-MIC concentrations
of azithromycin for 12 passages, with MICs determined after every passage. The
susceptibility of these isolates to a range of antibiotics was also determined before
and after serial azithromycin exposure.
Results: High level resistance (MIC >256mg/ml) developed within 8 passages for
3/6 Streptococcus isolates and within 4 passages for 3/6 Rothia isolates. Resistance
remained stable for these isolates following subculture in drug-free broth. The
MIC of the remaining Streptococcus and Rothia isolates also increased but not to
levels above the resistance breakpoints. Furthermore, 2/6 Rothia isolates developed
resistance to clindamycin following serial exposure to azithromycin.
Table: MIC ranges following azithromycin exposure
MIC range (mg/ml)
Passage 0 Passage 4 Passage 8 Passage 12
Streptococcus 0.064−6 1.5−>256 2−>256 4−>256
Rothia 0.023–0.125 0.064−>256 1−>256 1.5−>256
Conclusion: Exposure of clinical Streptococcus and Rothia isolates to azithromycin
can rapidly induce high level resistance, which appears to be stable.
Work supported by Wellcome Trust (CMcG) and Queen’s University Belfast (CK)
Vacation Scholarships.
70 Expression of RND-type efﬂux pumps as a mechanism of
antibiotic resistance in clinical Prevotella isolates
L. Sherrard1, B. Schaible1, D.F. Gilpin1, J.S. Elborn1, M. Tunney1. 1Queen’s
University Belfast, CF & Airways Microbiology Research Group, Belfast, United
Kingdom
Objectives: We have previously shown that CF associated Prevotella spp. are
resistant to antibiotics from multiple classes. It has also been demonstrated that
Prevotella possess either one or two species-speciﬁc RND-type efﬂux pumps. The
aims of this study where to determine if (1) efﬂux pumps are expressed by Prevotella
isolates and (2) expression of these pumps contributes to antibiotic resistance.
Methods: Transcription levels of the species-speciﬁc efﬂux pumps were analysed
in 31 clinical Prevotella isolates and Prevotella melaninogenica ATCC 25845 by
quantitative real time PCR (qRT-PCR). Minimum inhibitory concentrations (MICs)
of ceftazidime (n = 12 isolates), co-amoxiclav (n = 16 isolates) and tetracycline
(n = 22 isolates) were then determined by Etest® in the presence or absence of the
efﬂux pump inhibitor (EPI), Phe-Arg b-napthylamide 2HCl. The Wilcoxon Signed
Rank test was used to compare MICs before and after inhibition of efﬂux pumps.
Results: Twenty-six of 31 (84%) Prevotella isolates and the type strain expressed
the expected RND-type efﬂux pumps. For the remaining 5 isolates, either no
expression was detected (n = 3) or 1/2 expected pumps were expressed (n = 2). A
small but statistically signiﬁcant decrease in MICs for co-amoxiclav (P = 0.011,
Wilcoxon Signed Rank) and tetracycline (P< 0.001) was detected in the presence
of the EPI.
Conclusion: Most Prevotella isolates express RND-type efﬂux pumps, which may
contribute to co-amoxiclav and tetracycline resistance.
This work is supported by HSC Research and Development, Public Health Agency,
Northern Ireland and by the Medical Research Council through a US−Ireland
Partnership Grant.
71 Extended-spectrum b-lactamase (ESbL) production: a mechanism
of resistance to ceftazidime in Prevotella species isolated from
patients with CF
L. Sherrard1, T. Matier1, D.F. Gilpin1, M. Muhlebach2, J.S. Elborn1,
T. Schneiders1, M. Tunney1. 1Queen’s University Belfast, CF & Airways
Microbiology Research Group, Belfast, United Kingdom; 2UNC Chapel Hill, NC,
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Objectives: ESbL producing bacteria inactivate ceftazidime, which is used in the
treatment of CF lung infection. Ceftazidime resistance is common among CF
Prevotella isolates. The aims of this study were to determine and compare (1)
in vitro antimicrobial susceptibility to ceftazidime and (2) ESbL production by
Prevotella isolates from a range of sources.
Methods: Isolates of Prevotella (CF, n = 34; non-CF infections, n = 25; healthy
control, n = 17) were tested for susceptibility to ceftazidime by Etest® and for
ESbL production using the combined disc method. A chi-square test was used to
determine if there was an association between ESbL production and Prevotella
group. Isolates were split into ESbL positive/negative and MICs compared using
the Mann-Whitney test.
Results: Ceftazidime (CF and non-CF, MIC90 >256mg/ml; healthy controls, MIC90
128mg/ml) resistance was similar between groups. Twenty-ﬁve of 34 (77%) CF,
15/25 (60%) non-CF and 11/17 (65%) healthy control isolates were ESbL positive.
No association between ESbL production and Prevotella group was detected
(c2 = 1.252, P = 0.571). ESbL positive isolates had greater MICs against ceftazidime
(P < 0.001, Mann-Whitney test) compared to ESbL negative isolates.
Conclusion: ESbL production was common amongst Prevotella and was associ-
ated with reduced susceptibility to ceftazidime. CF Prevotella producing ESbLs
may potentially contribute to treatment failure of CF pulmonary infection with
ceftazidime.
Work supported by DEL NI and by HSC Research and Development, Public Health
Agency, NI and the MRC through a US−Ireland Partnership Grant. The non-CF
isolates were provided by Dr Hall, Anaerobe Reference Unit, Public Health Wales.
72 Inhalatory antibiotic therapy in cystic ﬁbrosis and emergence of
colistin resistant Gram-negative non-fermenting bacteria: a new
problem in pulmonary infection treatment?
P. Morelli1, E. Delﬁno1, R. Casciaro1, A. Formiga1, A. Pellettieri1, L. Fenu1.
1Giannina Gaslini Institute, Genoa, Italy
Objectives: The pulmonary infection in Cystic Fibrosis (CF) patients is charac-
terised by different Gram-negative non fermenting (GNnF) bacteria equipped with
intrinsic resistances to antibiotics that make more difﬁcult to treat this infection.
Colistin has emerged as a relevant therapeutic option for the treatment of GNnF.
Aerosol therapy has become increasingly important in the treatment of CF lung
disease. Nevertheless some studies report the emergence of new colistin-resistant
(COL-R) pathogens in CF. The aim of this study is to analyse the emergence of
COL-R GNnF bacteria in CF patients attending an Italian CF center.
Methods: During 2010–2012 were analysed 1865 strains of GNnF isolated from
Genoa CF patients.
The susceptibility to antibiotics was tested by Disk-diffusion and conﬁrmed by
E-test. The results were also correlated with clinical data of CF patients.
Results: The number of GNnF is increased from 30 to 58. The main of GNnF
recoverd are: A. xylosoxidans, S. maltophilia and P. aeruginosa. All GNnF strains
colistin resistant are multi-drug resistant, except some isolates of S. maltophilia.
The clinical data showed that the 65% of patients colonised by GNnF were treated
with cycles of nebulised colistin and alternated with nebulised tobramycin.
Conclusions: The emergence of COL-R GNnF strains in CF patients treated with
nebulised colistin suggest that this therapeutic option can select COL-R strains
and can favour the arising of other resistance to antibiotics. Then the isolation of
these GNnF bacteria present a real challenge to diagnostic laboratories, as they are
difﬁcult to identify and often misidentiﬁed as belonging to the B. cepacia complex.
